All News
Weight Loss as a Therapeutic Goal in Psoriatic Arthritis
Psoriatic arthritis (PsA) is a complex inflammatory disease often complicated by obesity, which not only worsens disease activity but also impairs treatment response. At ACR Convergence 2025, three compelling studies spanning pharmacologic, lifestyle, and longitudinal observational data converged on a central theme: weight loss is a powerful modulator of PsA outcomes, regardless of the intervention used.
Read Article
IgG4: Rare, but new treatments on the horizon
IgG4 is a rare autoimmune disease with excessive IgG4 immunoglobulins that can affect multiple organs yielding plasma cell deposition (inflammation) and fibrosis.
Read Article
Upadacitinib: revisiting safety data in RA and GCA
For the last several years, conversations about JAK inhibitors have often started and ended with safety. The shadow cast by ORAL Surveillance has made clinicians more cautious and regulators more restrictive.
Read Article
#ACR25 Abstr#LB20 At EULAR, data for Phase 3 RCT of Deucravacitinib, Tyk2-i in active #PsA showed ACR20 was met at WK16. Here, data showed sustained response through WK 52 across core domains inc. those who switched PBO->DEU. No major safety assoc. with JAK-i.A few acne @RheumNow https://t.co/tmzQMOtjev
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
POETYK PsA-1 (one of paired deucravacitinib in PsA ph3 registration studies)
Oral med
Good outcomes
Safety very good
but the bar is very high nowadays in PsA
Questions splicing through depth of response
Definitely will find a place in therapy, but where?
#ACR25 LB19 @RheumNow https://t.co/iqmHQrMTYN
Links:
David Liew drdavidliew ( View Tweet)
POETYK PsA 1 and 2 Deucravacitinib TYK2 inhibitor Ph3 RCT
52 wks data
Deucra 336pts PBO 334pts then crossover wk 16 to 52
Pooled analysis wk 16
ACR 20 54% vs. 31%
Enthesitis reduction LEI 52% vs. 45%
Dactylics resolution 58% vs. 44%
POETYK-PsA 1 Wk 52
ACR 20 63%
ACR50 44%
PASI https://t.co/LYJbU8fYwI
Links:
Aurelie Najm AurelieRheumo ( View Tweet)
In POETYK PsA-1, deucravacitinib showed sustained efficacy through Week 52 in PsA, improving joint, skin, PROs, and radiographic progression. Safety remained favorable with no new signals. TYK2 inhibition continues to show promise. Abstract#LB20 @RheumNow #ACR25 https://t.co/sGkk062HqJ
Antoni Chan MD (Prof) synovialjoints ( View Tweet)
Questions #ACR25 LB20 to Paul Emery on rosnilimab:
Fleischmann: could be induction therapy? (Not intent, but could be)
Choy: Depth of changes with translational data
Tanaka: Safety given peresolimab ph2b here (diff epitope, membrane proximity, targeted depletion PD-1hi)
@RheumNow
David Liew drdavidliew ( View Tweet)
Mease et al. 52 week results deucravacitinib in PsA. Approx ACR20 60%, ACR50 40%, ACR70 25%. Sustained radiographic benefit. No new safety signals @RheumNow #ACR25 Abstr#LB20 https://t.co/vKqjb08mI8
Richard Conway RichardPAConway ( View Tweet)
PD-1 agonist as an induction therapy in refractory RA??
Rosnilimab ph2b:
- still responding 3mo after Rx stopped
- no difference between type of prior b/tsDMARD failure
- safety here looks good *so far*
A lot of cautious excitement in the room for this
#ACR25 LB19 @RheumNow https://t.co/CmfPlP4g0N
Links:
David Liew drdavidliew ( View Tweet)
A new approach in RA:
Rosnilimab targets & depletes PD-1–high pathogenic T cells, acting upstream of cytokine pathways. In Ph2b, all doses improved DAS28-CRP & ACR responses vs placebo, with durable efficacy & good safety.
@RheumNow #ACR25 Abstract#LB19 https://t.co/cIxi7NEu6C
Jiha Lee JihaRheum ( View Tweet)
#ACR25 Abstr#LB19 New T-cell therapy on the block! In Phase 2b RCT of #RA (~50% b/tsDMARD-IR), Rosnilimab, PD-1 agonist met its endpoint (DAS28-CRP) at WK12. Effective despite type of previous therapy. No safety concern/malignancy/death. To proceed to Phase 3 @RheumNow #ACRBest https://t.co/MecTYMpH0o
Links:
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Emery et al. Rosnilimab, selective T cell (PD-1high Tph/Tfh, Teff) monoclonal antibody in RA. Phase 2 RCT. 424 patients. 41% prior bDMARD. 69% CDAI LDA week 14. Week 12 ACR20 70%, ACR50 40%, ACR70 21%. @RheumNow #ACR25 Abstr#LB19 https://t.co/479q6COWvk
Richard Conway RichardPAConway ( View Tweet)
b/tsDMARD in RA + CKD (eGFR <60)
From >12K pts in CorEvitas:
- overall effective but 30% ↓ CDAI-emission (HR 0.71)
- Findings consistent across TNFi, IL-6i, ABA BCDT, JAKi
@RheumNow #ACR25 A#2640 https://t.co/UOP9ejZKoA
Jiha Lee JihaRheum ( View Tweet)
🎥 LIVE from #ACR25
Join us daily at 5 PM CST for RheumNow’s ACR Recap Live -
Your must-watch debrief of the day’s biggest breakthroughs, hot abstracts, and real-time clinical takeaways.
Streaming on YouTube Live, Facebook Live, X-Live & LinkedIn Live.
Save the time. Be part of https://t.co/beh3bEL8fs
Dr. John Cush RheumNow ( View Tweet)
📊 NEW FROM EULAR: Real-world effectiveness of switching to a JAKi after first-line TNFi in PsA
See how second-line treatment choices impacted TJC and SJC in patients from the Adelphi database. Poster sponsored by AbbVie Medical Affairs + Health Impact.
https://t.co/2R84O54xeI https://t.co/lZKiIvsixf
Dr. John Cush RheumNow ( View Tweet)
RheumNow’s expanded coverage of the #ACR25 annual meeting is sponsored by Bristol Myers Squibb, Novartis, and UCB. All coverage content is independently selected by RheumNow and its faculty.
Dr. John Cush RheumNow ( View Tweet)
Secrets and Pearls in Rheumatology https://t.co/SwnlB8UbHO
@Janetbirdope pearls in rheumatology.
Sero negative inflammatory arthritis ? Or is it? Look at the toes for early signs of PsA.
In my clinic ITS inflammatory arthritis to determine etiology .
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
Secukinumab vs Ustekinumab in PsA https://t.co/EylYHtRWsj
@synovialjoints Elaborate more on head to head trial in PsA , in a population who failed TNF biologic.
@RheumNow
#ACR25
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
What's the latest in PsA? https://t.co/I8ZgRQpVy6
Great review for whats new in PsA by @drpnash
Looking forward for Large IL23-Axial study results.
@RheumNow
#ACR25
Links:
Nouf Al hemmadi NoufAhmedAlham2 ( View Tweet)
